Venture-Backed Startups
131,038 companies with verified investor relationships.
Cytofacto appears to be a Japanese startup involved in cell therapy / regenerative medicine, engaging in contract manufacturing of cell-based products (e.g. an agreement regarding manufacturing of "Stemchymal"). The page does not provide a full description of the company's offerings.
2 investors
0 investors
0 investors
CytoGen Lab develops liquid biopsy technology for cancer detection through circulating tumor cell (CTC) isolation from blood samples, combining biotechnology and engineering for precision medicine applications.
2 investors
0 investors
Cytoki Pharma is a clinical-stage biotechnology company developing IL-22-based medicines for metabolic diseases such as obesity and type 2 diabetes, and conditions involving epithelial injury like inflammatory bowel disease. Its lead candidate, CK-0045, is a long-acting IL-22 analogue in Phase 2 clinical evaluation for cardiometabolic diseases.
2 investors
Cytokinetics develops potential medicines for cardiovascular and neuromuscular diseases characterized by impaired muscle function. The company specializes in sarcomere-directed therapies targeting conditions involving muscle weakness, loss, and dysfunction.
1 investor
Cytomos develops AuraCyt®, a microelectronics-based biotechnology platform for real-time single-cell analytics in bioprocessing and cell and gene therapy manufacturing. The company serves large biotech and pharma companies seeking cost-effective process analytical technology solutions for drug development and manufacturing.
1 investor
CytomX is a clinical-stage biopharmaceutical company developing conditionally activated biologic cancer therapies, including antibody-based treatments designed to target tumors while limiting effects on healthy tissue. It advances a pipeline of Probody therapeutics through preclinical research and clinical trials in oncology.
3 investors
Clinical-stage biotechnology company developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment.
1 investor
0 investors
Cytonics develops biologic therapies targeting osteoarthritis, with lead candidate CYT-108, a recombinant protease inhibitor for knee joint regeneration based on a novel pathway to restore cartilage-secreting cells. The company funds development through equity crowdfunding from individual investors rather than venture capital.
0 investors
0 investors
Cytora provides AI-powered risk processing software for commercial insurance carriers and brokers to automate underwriting, claims decisions, and portfolio management. The platform enables digital-first workflows that reduce operational costs while improving risk selection and decision-making across the insurance value chain.
3 investors
Cyto Recovery develops technology for label-free cell sorting and gentle sample cleanup for cell populations, aimed at life-science and research users. Its products are positioned as tools for separating and purifying cells without labeling.
1 investor
Cytos is an orthobiologics company that develops biologic treatments for orthopedic conditions. The company serves orthopedic surgeons and patients requiring spine, foot, ankle, and other orthopedic interventions.
1 investor
Hone Bio is a pre-clinical biotech company developing NanoPilot lipid nanoparticle (LNP) targeting technology for extrahepatic drug delivery, engineering LNPs to target specific cell types while blocking off-target liver uptake. It serves therapeutic developers seeking to deliver treatments such as mRNA-based therapies beyond the liver.
1 investor
0 investors
Cytosolix uses its Tumor Activated Permeability (TAP) platform to redesign small molecule oncology drugs into weakly-acidic derivatives that exploit tumor acidity to selectively target and accumulate in solid tumors while sparing healthy tissue. Based on research from Yale University, its pipeline includes an androgen receptor inhibitor for early-stage prostate cancer and additional inhibitors for breast and other cancers.
2 investors
0 investors
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers. The company is building a portfolio of immune cell engagers aimed at cancer therapies.
5 investors
0 investors
0 investors
Cytotrait develops genetic technologies for crop improvement through chloroplast engineering. The company applies proprietary MOSS technology to enable precise DNA mutagenesis in plant genomes for agricultural biotechnology applications.
2 investors